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A B S T R A C T
A resazurin-based cell viability assay was developed for phenotypic screening of the LOPAC 1280 ‘library
of pharmacologically active compounds’ against bloodstream forms of Trypanosoma brucei in vitro
identifying 33 compounds with EC50 values <1 mM. Counter-screening vs. normal diploid human
ﬁbroblasts (MRC5 cells) was used to rank these hits for selectivity, with the most potent (<70 nM) and
selective (>700-fold) compounds being suramin and pentamidine. These are well-known antitrypa-
nosomal drugs which demonstrate the robustness of the resazurin cell viability assay. Themost selective
novel inhibitor was (+)-trans-(1R,2R)-U50,488 having an EC50 value of 60 nM against T. brucei and 270-
fold selectivity over human ﬁbroblasts. Interestingly, ()-U50,488, a known CNS-active k-opioid
receptor agonist and other structurally related compounds were>70-fold less active or inactive, as were
several m- and k-opioid antagonists. Although (+)-U50,488 was well tolerated by the oral route and
displayed good pharmaceutical properties, including high brain penetration, the compound was not
curative in the mouse model of infection. Nonetheless, the divergence of antinociceptive and
antitrypanosomal activity represents a promising start point for further exploratory chemistry.
Bioinformatic studies did not reveal any obvious candidate opioid receptors and the target of this
cytostatic compound is unknown. Among the other potent, but less selective screening hits were
compound classes with activity against protein kinases, topoisomerases, tubulin, as well as DNA and
energy metabolism.
 2010 Elsevier Inc.
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HumanAfricantrypanosomiasis (HAT) isadiseaseendemictothe
sub-Saharan region of Africa and is caused by two subspecies of the
protozoanparasiteTrypanosomabrucei.T. b. gambiense is responsible
for the chronic form of the disease found in western and central
Africa, accounting for over 90% of reported cases of the disease,
whereasT. b. rhodesiense is responsible for themoreacute formof the
disease located in eastern Africa [1]. Only 10–15% of the 60 million
people at risk of the disease are under surveillance [1] and the death
rate is currently estimated at 30 000 per annum [2]. T. b. brucei and
other Trypanosoma spp. are responsible for related veterinary
diseases of economic importance, such as nagana in cattle.
Of the four drugs that are currently registered for use against
HAT, pentamidine and suramin are used against the early stage of
the disease; and melarsoprol and eﬂornithine (diﬂuoromethylor-
nithine, DFMO) are used against the late stage of the disease, when
the infection has spread to the central nervous system (CNS). These* Corresponding author. Tel.: +44 1382 385155; fax: +44 1382 385542.
E-mail address: a.h.fairlamb@dundee.ac.uk (A.H. Fairlamb).
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Open access under CC BY license.treatments are beset with problems such as difﬁculties in
administration (none are given orally), cost, duration of treatment,
toxicity and resistance [3]. Melarsoprol treatment is highly toxic
and responsible for iatrogenic deaths in 5% of patients. Eﬂornithine
therapy is only effective against T. b. gambiense infections and
presents severe economic and logistical problems in resource poor
settings due to the need for 4 daily intravenous infusions over 14
days [4]. A recent clinical trial suggests the duration and frequency
of treatment can be reduced by combination of eﬂornithine with
nifurtimox [5], which may act as an interim solution until better
and safer drugs are developed. The recent failure of the ﬁrst orally
active ﬁrst stage drug, pafuramidine (DB289) [6], and rumours of
increasing failures with eﬂornithine therapy underlines the urgent
need for novel therapeutics.
Whilst many dominant paradigms of drug discovery focus on
screening against molecular targets [7], there has been a
resurgence of interest in phenotypic screening against whole
parasites [8]. Phenotypic screening, particularly when in combi-
nation with a mammalian counter-screen, has the distinct
advantage of addressing key druggability and toxicity issues early
in drug discovery, thereby reducing attrition at later stages in
development. In some cases phenotypic screening may identify
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However, understanding the mode of action of phenotypic
screening hits can prove challenging since many drugs act by
modulation of multiple intracellular targets (‘‘network pharma-
cology’’) [9]. Hit identiﬁcation for novel targets is best approached
with a screening library of diverse chemical space, but whole cell
assays typically have a much lower throughput than molecular-
target-based screens. Hence, we chose to screen a library of known
pharmacologically active compounds against T. brucei cultured in
vitro and to counter-screen actives against a human ﬁbroblast cell
line (MRC5 cells) to eliminate non-selective inhibitors. Potent and
selective hits from such an approach can present exploitable
shortcuts, particularly if they have already been used in humans
with known dosing and toxicity information. Developing these hits
could represent a low-risk, low-cost strategy for tackling orphan
diseases of the poor [7].
The Library of Pharmacologically Active Compounds from
Sigma–Aldrich (LOPAC 1280; international version) contains 1268
compounds that are ligands for many enzymes, receptors and ion
channels in other organisms. Many are drug-like molecules and
some are CNS active—an important consideration when seeking a
replacement therapy for late-stage trypanosomiasis. Herewe report
over30compoundswithEC50valuesagainstT.brucei less than1mM,
a concentration that should be readily achieved in plasma. Of these,
one third have >20-fold selectivity with the k-opioid receptor
agonist U50,488 showing the greatest potency and selectivity. Some
preliminary structure–activity relationshipsofCNS-activem- andk-
opioid receptor agonists and antagonists are reported.
2. Materials and methods
2.1. Chemicals and materials
The LOPAC 1280 library (international version) was purchased
from Sigma–Aldrich (Gillingham, UK). Pentamidine isethionate
was obtained from Research Biochemicals International, eﬂor-
nithine was a gift fromMerrell Dow Research Institute (Ohio, USA)
and melarsoprol a gift from Rhone-Poulenc (France). U69593,
U5449A and naloxone were obtained from Alexxis Biochemicals
(Nottingham, UK). Norbinaltorphimine, ()-U50,488, (+)-U50,488,
naltrexone, DIPPA (2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-
(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide hy-
drochloride) and 4-P-PDOT (cis-4-phenyl-2-propionamidotetra-
lin) were obtained from Tocris Bioscience (Avonmouth, UK). DMSO
was purchased from VWR international and HPLC-grade methanol
and acetonitrile from Fluka. Resazurin, thioglycerol and PEG400
were obtained from Sigma–Aldrich (Gillingham, UK). Sterile 96-
well plates were obtained from Greiner Bio-one (Stonehouse, UK).
2.2. Trypanosome culture
Bloodstream-form T. b. brucei cells (strain 427, ‘single marker’)
were grown at 37 8C and 5% CO2 in a modiﬁed HMI9 medium [10]
(HMI9-T where 0.2 mM 2-mercaptoethanol was replaced with
0.056 mM thioglycerol). Stock cultures were maintained in T75
vented cap culture ﬂasks (Greiner, Stonehouse, UK) and sub-
cultured every 2–3 days by 500-fold dilution into fresh medium.
For microtitre plate assays, cells were counted using a Casy cell
counter TT (Sharfe systems) and diluted appropriately.
2.3. Mammalian cell culture
Normal humanMRC5 cells (diploid foetal lung ﬁbroblasts) were
used as a counter-screen for non-selective inhibitors. Stabilates
were obtained from the European Collection of Cell Cultures
(ECACC) were grown at 37 8C and 5% CO2 in a humidiﬁed incubatorin Eagle’s Minimal Essential Medium (Sigma–Aldrich, Gillingham,
UK) supplemented with 10% foetal bovine serum (Invitrogen,
Paisley, UK). Stock cultures were maintained in T75 vented cap
culture ﬂasks with half the medium changed each day. Cells were
split once conﬂuent as follows: medium was removed and the
monolayer washed with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4, pH 7.4). Cells were detached by
incubation for 2 min with 1 ml of trypsin EDTA solution
(0.5 mg ml1 trypsin, 0.2 mg ml1 EDTA4Na in Hanks balanced
salt solution supplied by Invitrogen, Paisley, UK). Detachment was
conﬁrmed by microscopy. Fresh medium was added to the cells to
subculture into new ﬂasks at 2- to 4-fold the original volume as
required.
2.4. Linearity of assay
T. brucei bloodstream-form cells and human ﬁbroblasts were
pipetted into 96-well plates to give a range of densities in a total
volume of 200 ml culture medium. Resazurin (20 ml of a 500mM
stock; 45.5mM ﬁnal concentration) was added immediately to T.
brucei cells or the next day for human ﬁbroblasts, following
incubation overnight to allow attachment to the plastic plates.
Fluorescence was then measured at intervals up to 5 h (excitation
of 528 nm and emission of 590 nm) on a Biotec Instruments FLX
800 ﬂuorescent plate reader.
2.5. DMSO tolerance of the assay
DMSO was serially diluted across a 96-well plate in 200 ml of
the appropriate medium. For T. brucei, 100ml aliquots were then
transferred to a plate containing 100ml cells at 2  103 ml1.
Human ﬁbroblasts were plated at 2  104 ml1 in 100 ml of
medium and incubated overnight to allow cells to adhere before
the addition of medium containing DMSO (100ml) over a range of
concentrations. Parasites and mammalian cells were then incu-
bated for 3 days, after which 20 ml 500-mMresazurin was added to
eachwell. Plates were incubated for a further 4 h beforemeasuring
ﬂuorescence as above.
2.6. EC50 determinations against T. brucei
Test compounds were dissolved in DMSO at 20 or 10 mMexcept
for eﬂornithine which was dissolved in water and sterilised by
ﬁltration. The control drug (pentamidine) was dissolved in DMSO at
100mM.HMI9-Tmedium(148.5ml)wasaddedtocolumn2(B2-G2)
of a sterile 96-well culture plate. HMI9-T + 1% DMSO (100ml) was
added to all remainingwells. Test compound solutions (1.5ml)were
added to column 2 (B2-G2). Pentamidinewas placed on row G of all
plates as a control. Threefold serial dilutions were carried out by
transferring 50ml from column 2 to the adjacent column (100ml).
The process was repeated up to column 10. HMI9-T containing
2 103 trypanosomes ml1 (100ml) was added to all wells except
column 1. HMI9-T (100ml) was added to column 1. Columns 1 and
11 served as controls without cells and without test compound,
respectively. Cells were incubated for 3 days, after which 20ml
0.5 mM resazurin was added to each well, before measuring
ﬂuorescence after4 h incubation.DatawereprocessedusingGRAFIT
(version 5.0.4; Erithacus software) and ﬁtted to a 3-parameter
equation,where the data are corrected for backgroundﬂuorescence,
to obtain the effective concentration inhibiting growth by 50%
(EC50):
y ¼ ymax
1þ ði=EC50Þs
(1)
where ymax is the uninhibited ﬂuorescence value, i is the inhibitor
concentration and s is the Hill slope of the curve.
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separate occasions and the mean weighted to the standard error
calculated using the following formulas, where ‘a’ is the standard
error of EC50 determination ‘A’, etc.
weighted mean ¼ ðA=a
2Þ þ ðB=b2Þ þ ðC=c2Þ
ð1=a2Þ þ ð1=b2Þ þ ð1=c2Þ
(2a)
and
error ¼ ð1=aÞ þ ð1=bÞ þ ð1=cÞð1=a2Þ þ ð1=b2Þ þ ð1=c2Þ (2b)
2.7. Production of LOPAC daughter plates
Latch-racks containing the LOPAC library at 10 mM dissolved in
DMSO were stored frozen at 20 8C. Racks were thawed at room
temperature for 3 h and centrifuged in a BeckmanCS-15R centrifuge
at 1100  g for 2 min to return any condensation on the lids to the
solution. Racks were thenmixed vigorously for 5 min on a platform
shaker. Aliquots (50ml) of each rackwere transferred tov-bottomed
polypropylene 96-well plates (Matrix) using a Janus liquid handler
(PerkinElmer) to create a primary daughter set. DMSO (98ml) was
plated out to columns 2–11 of fresh v-bottom polypropylene 96-
well plates using a Precision 200 liquid handler (Biotek). An aliquot
(2ml) of the primary daughter set was transferred to the DMSO-
containing plates using a Platemate 2X2 liquid handler (Matrix) to
create secondary daughter sets at 200mM. At this stage, 50ml of
200mM pentamidine was added to wells E1–H1, 50ml DMSO was
added to the remainingwells of columns 1 and 12 for use as control
wells. Duplicate daughter sets (set A and set B) created in this way
wereused for two independent screeningruns tocontrol forerrors in
liquidhandling. Daughter setswere sealedusinga nitrogen-ﬂushing
heat sealer (K Biosystems) and stored at 20 8C.
2.8. Screening of the LOPAC library against T. brucei
Daughter sets were thawed and mixed thoroughly, before 1 ml
was transferred to an empty 96-well tissue-culture plate (Greiner)
using a Platemate 2X2 liquid handler (Matrix). Plates were
transferred to a tissue culture hood and 180ml medium was
added to each well using a WellMate dispenser (Matrix). HMI9-T
(19 ml) was added to wells A1–D1 and 19 ml medium containing T.
brucei (1.05  104 ml1) was added to all other wells using a
Imact2 pipettor (Matrix). Wells A1–D1 served as background (no
cell) controls;wells E1–H1 served as pentamidine controls (1 mM);
and column 12 served as a full signal control (cells, no compound).
Plates were incubated for 3 days after which 20 ml 0.5 mM
resazurin was added to each well. Plates were incubated for a
further 4 h before measuring ﬂuorescence as above. Fluorescence
signal for each well was background subtracted and expressed as
percentage of the full signal controls. Z-prime (Z0) values were
calculated for all plates using the following equation [11]:
Z0 ¼ 1 3sðfull signalÞ þ 3sðbackground signalÞ
mðfull signalÞ mðbackground signalÞ (3)
where m and s represent the means and standard deviations,
respectively
2.9. EC50 determinations against mammalian cells
Compounds with submicromolar EC50 values against T. brucei
were tested against human ﬁbroblasts as follows. Cells were
detached, counted as described above and diluted to
2  104 ml1. Cells (100ml) were added to columns 1–11 and
100mlmediumwas added to column12of a96-well plate. Theplatewas then incubated for 24 h to allow attachment. Test compounds
and Doxorubicin as a control, were serially diluted in DMSO in a 96-
well polypropylene v-bottomed plate using a Janus liquid handler
(PerkinElmer). Samples from the test compound dilution series and
QC plates (2ml) were transferred to duplicate tissue culture 96-well
plates using a Platemate 2X2 liquid handler (Matrix). These plates
were transferred to a tissue culture hood and 200ml medium added
to all wells. From these plates, 100ml was transferred to the cell-
containingplates setupthepreviousday. Plateswere incubatedfor3
days after which 20ml 0.5 mM resazurin was added to each well.
Plates were incubated for a further 4 h before measuring ﬂuores-
cence as above. Fluorescence signal for each well was background
subtracted and expressed as percentage inhibition of the full signal
control wells. EC50 curve ﬁtting employed a 4 Parameter Logistic
dose response curve using IDBS XLFit 4.2 Model 205:
y ¼ Aþ B A
1þ ðC=xÞD
(4)
where A is the minimum y-value, B is the maximum y-value, C is
the EC50, and D is the Hill slope. All test compound curves had
ﬂoating maximum and minimum and pre-ﬁt was used for all 4
parameters.
2.10. Homology searching and protein alignments
Sequences fork-opioid receptor protein were retrieved from the
National Centre for Biotechnology Information (http://www.ncbi.
nlm.nih.gov/) for sheep (accession AAY66995), zebraﬁsh (accession
NP_878306), rough skinned newt (accession AAU15126), mouse
(accession NP_035141 and AAA56759) and guinea pig (accession
AAA67171). Global alignmentswere carried out using ClustalW and
T. brucei GeneDB was searched using the TBLASTN algorithm [12].
2.11. Effect of (+)-U50,488 on cell growth
Flasks of T. brucei were seeded at 1  104 cells ml1 and
incubated in the presence of the known inhibitors pentamidine
and eﬂornithine, and the LOPAC hit (+)-U50,488 for 3 days. Flasks
were set up in triplicate for each inhibitor at multiples of EC50
along with 3 control ﬂasks with no inhibitor added. Pentamidine
and (+)-U50,488 were added in DMSO in a volume of 0.1% of the
culture. Eﬂornithinewas dissolved directly in HMI9-Tmedium and
sterilised by 0.22 mMﬁltration before diluting into the cell culture.
Cell densities were determined at intervals using a haemocyt-
ometer and generation times calculated using GraFit (version
5.0.13; Erithacus software) using the following equation:
N ¼ N02t=g (5)
where N0 and N are the number of cells at time zero and time t,
respectively, and g is the time per generation. For low cell densities,
samples were concentrated 150-fold by centrifugation and
resuspension in an appropriate volume of medium.
2.12. DMPK and efﬁcacy studies
All animal experiments were carried out following local ethical
review and under UK regulatory licensing in accordance with the
European Communities Council Directive (86/609/EEC). NMRI
outbred mice were purchased from Harlan laboratories, UK.
In brief, a 96-well equilibrium dialysis apparatus (HT Dialysis
LLC, Gales Ferry, CT) was used to determine the free fraction in
plasma for (+)-U50,488. Membranes (12–14 kDa cut-off) were
conditioned in deionised water for 60 min, followed by condition-
ing in 80:20 deionisedwater:ethanol for 20 min, and then rinsed in
isotonic buffer before use. Frozen female mouse plasma was
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(10 mg g1), and 150-ml aliquots (n = 6 replicate determinations)
loaded into the 96-well equilibrium dialysis plate. Dialysis against
isotonic buffer (150ml) was carried out for 5 h at 37 8C using an
orbital microplate shaker at 125 revolutions min1. At the end of
the incubation period, aliquots of plasma or buffer were
transferred to Micronic tubes (Micronic B.V., the Netherlands)
and the composition in each tube balanced with control ﬂuid, such
that the volume of buffer to plasma is the same. Sample extraction
was performed by the addition of 400 ml of acetonitrile containing
a structural analogue of (+)-U50,488 as internal standard. Samples
were allowed to mix for 1 min and then centrifuged at 2100  g in
96-well blocks for 10 min. All samples were analysed by UPLC/MS/
MS on a Quattro Premier XE Mass Spectrometer (Waters
Corporation, USA) and the unbound fraction determined as the
ratio of the peak area in buffer to that in plasma.
To determine brain penetration, (+)-U50,488 was administered
intravenously to female NMRI mice (n = 3) at a dose level of
2 mg kg1 (freshly prepared in 5% DMSO, v/v, in sterile saline). A
blood sample (50 ml) was collected by cardiac puncture from each
animal into Micronic tubes containing deionised water (100ml) at
5 min post-dose and the brain of each animal removed into tared
Covaris glass tubes. Blood and brains were stored at 80 8C until
analysis.
To determine exposure, (+)-U50,488 was administered by oral
gavage using a 20-gauge feeding tube ﬁtted with a 1-ml syringe to
female NMRI mice (n = 3) at a dose level of 150 mg kg1 (freshly
prepared in DMSO, PEG400, milliQ water (1:8:11, v/v, respective-
ly)). Blood samples (10 ml) were collected from the tail vein of each
animal into Micronic tubes containing deionised water (20 ml) at
0.25, 0.5, 1, 2, 4, 6 and 8 h post-dose and stored at 80 8C until
analysis.
For analysis, brain tissuewashomogenised in50% (v/v)methanol
in deionised water (1:2, w/v) using a Covaris S2 (K Biosciences,
Hoddesdon, UK). Extraction of blood and brain samples was then
performed by a method based on protein precipitation using
acetonitrile containing a structural analogue of (+)-U50,488 as an
internal standard. Levels of (+)-U50,488 were determined in these
extracted samples by UPLC–MS/MS on a Quattro Premier XE mass
spectrometer (Waters Corporation, USA). A calibration curve was
constructed inbloodandbrainhomogenate to cover at least 3 orders
of magnitude for (+)-U50,488 (range 2–2000 ng ml1).
For the efﬁcacy study, groups of three female NMRI mice were
infected with the bloodstream form of T. b. brucei (strain 427) by a
single intraperitoneal injection of 104 parasites in 0.2 ml HM19-T
medium. Three days following infection,micewere either dosed by
oral gavage with (+)-U50,488 (150 mg kg1, freshly prepared in
DMSO, PEG400, milliQ water (1:8:11, v/v, respectively)) or left
untreated. Dosing of (+)-U50,488 treated mice was then repeated
in an identical manner every 4 h for a further 32 h. Thereafter,
animals were inspected daily for clinical signs of infection and wet
smears of tail blood were examined microscopically as appropri-
ate. Parasitaemia was determined using a Neubauer haemocyt-
ometer andmiceweremonitored for 30 days.Mice that exceeded a
parasitaemia >108 ml1 were humanely killed since prior experi-
ence indicated that animals would succumb to an overwhelming
infection by the following day.
3. Results
3.1. Linearity of the resazurin cell viability assays
AlamarBlue1 has been used previously as an in vitro viability
assay for T. brucei [13]. This proprietary reagent contains resazurin
[14], a dye which is metabolically reduced in cells to the highly
ﬂuorescent product resoruﬁn. Using the less expensive and widelyavailable reagent resazurin, the linearity and dynamic range of the
assay was determined for parasite and human ﬁbroblasts. To
determine the dynamic range of the assay, bloodstream forms of T.
bruceiwere incubated at 37 8C in culture medium at a range of cell
densities containing 440mM resazurin and ﬂuorescencemeasured
at intervals. For each time point ﬂuorescence was proportional to
cell density with linear correlation coefﬁcients (r2) >0.997
(Fig. 1A). Likewise, ﬂuorescence increased linearly with time at
any cell density (Fig. 1C, r2 > 0.996). Thus, ﬂuorescence is
proportional to cell density up to 2  105 cells per well within a
2–5 h incubation period. Similar results were obtained for human
ﬁbroblasts (Fig. 1B and D) up to 3  104 cells per well within a 2–
6 h incubation. In further assays, ﬁnal cell densities and resazurin-
incubation times did not exceed these ranges.
3.2. DMSO tolerance of the resazurin cell viability assays
Test compounds were supplied as 10 mM stocks dissolved in
DMSO and so it was necessary to determine the tolerance of the
assays for this solvent. Both cell lines showed a similar sensitivity
to DMSOwith IC50 values of 0.80  0.06 and 1.04  0.08% (v/v) for T.
brucei and human ﬁbroblasts, respectively (data not shown). DMSO
(0.5%)was selected as an acceptable compromise allowing compound
addition up to 50 mMwith an acceptable attenuation of ﬂuorescence
of 20% for the T. brucei assay and 15% for the MRC5 assay. All
subsequent assays contained 0.5% DMSO.
3.3. Sensitivity to standard drugs
Five drugs currently used in treatment of HAT were tested for
growth inhibition (Fig. 2A). The most potent of these were
pentamidine, suramin andmelarsoprol, with EC50 values in the low
nanomolar range, similar to those published for T. b. rhodesiense
and T. b. gambiense by Raz et al. [13] and for various T. b. gambiense
stocks by Likeufack et al. [15]. Eﬂornithine was the least effective
drug (EC50 22.4  1.1 mM). Since eﬂornithine induces physiological
activation ofmitochondrialmetabolism [16], it could potentially yield
erroneous results due to increased reduction of resazurin in drug-
treated cells. However, this does not appear to be the case as direct
counting of cell growth returned a similar EC50 of 17.1  0.1 mM.
Nifurtimox was intermediate in potency (EC50 1.8 mM) in good
agreement with previous reports [17,18]. These results provide
further validation of resazurin as a suitable substitute for alamar-
Blue1 reagent. Pentamidine isethionate was chosen for use as a ‘per-
plate’ control for all future assays. Similarly, the anticancer compound
doxorubicin [19] was used as a control for MRC5 assays (Fig. 2B).
3.4. Screening of the LOPAC collection
Initially, the LOPAC collection of pharmacologically active
compounds was screened against T. brucei at a ﬁxed concentration
of 1 mM on two independent occasions. This identiﬁed 52
compounds producing a mean signal of less than 50% of the
control on at least one occasion: an initial hit rate of 4.3%. Hitswere
analysed by LC–MS conﬁrming a purity of at least 95% for all
compounds (data not shown).
Triplicate independent EC50 determinations were carried out
for each of these hits against T. brucei. The resulting EC50 values for
each hit were in good agreement with coefﬁcients of variation
typically less than 20%. Means weighted to standard error for each
compound were determined and at this point 19 hits with EC50
values of greater than 1 mM were rejected (Table 1), leaving 33
conﬁrmed submicromolar EC50 hits against T. brucei (Table 2).
Selective activity against the parasite is an essential feature of
drug leads [20]. We therefore determined EC50 values of our hits
against MRC5 cells, a human embryonic lung cell line used in
[(Fig._1)TD$FIG]
Fig. 1. Linearity of the resazurin-based assay. T. brucei bloodstream-form cells (panels A and C) or human ﬁbroblasts (panels B and D) were diluted across a range of densities
on 96-well plates. Resazurin was added immediately in the case of T. brucei or the following day for human ﬁbroblasts. Fluorescence signal from T. brucei plates was
proportional to cell density at various time points (panel A, open circles 2 h; closed circles 3 h; open squares 4 h; closed squares 5 h) and linear with respect to time at various
cell densities (panel C, open circles 1  106 cells per well; closed circles 5  105 cells per well; open squares 2.5  105 cells per well; closed squares 1.25  105 cells per well).
Fluorescence signal fromMRC5 plateswas proportional to cell density at various time points (panel B, open circles 1 h; closed circles 2 h; open squares 3 h; closed squares 4 h;
open triangles 5 h; closed triangles 6 h) and linear with respect to time at various cell densities (panel D, open circles 1  104 cells per well; closed circles 1.5  104 cells per
well; open squares 2  104 cells per well; closed squares 2.5  104 cells per well; open triangles 3  104 cells per well).
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resulting 4 determinations were typically less than 40%. Means
weighted to standard error were determined and used to calculate
the fold-speciﬁcity for T. brucei over human ﬁbroblasts (Table 2).
Two known trypanocidal drugs, pentamidine and suramin, which
happen to be present in the LOPAC library returned speciﬁcities of
3500- and >700-fold, respectively. The highest speciﬁcity of the
remaining hits (270-fold) was demonstrated by (+)-U50,488, with
an EC50 of 59 nM. The mixture of enantiomers, ()-U50,488,
[(Fig._2)TD$FIG]
Fig. 2. Response of T. brucei and human ﬁbroblasts to standard drugs. T. brucei, 200 cells
with a range of inhibitor concentrations. Resazurin was added approximately 4 h befor
minus inhibitor. The EC50 values determined were as follows: pentamidine (open circles
20.1  1.1 nM; nifurtimox (closed squares) 1.81  0.13 mM; eﬂornithine (open triangles) 2showed a similar speciﬁcity, but only half the potency of the 1R,2R
trans enantiomer, suggesting that the growth inhibition is largely due
to (+)-U50,488. Only two other hits returned speciﬁcities greater than
100-fold: dequalinium dichloride, an broad-range antimicrobial
known to act against plasmodium in mice [22] and oligomycin A, a
macrolide antibiotic that inhibits membrane associated mitochon-
drial ATPase [23]. Only one compound (vincristine sulfate, an
inhibitor of microtubule assembly [24]) demonstrated greater
speciﬁcity for human ﬁbroblasts compared to T. brucei. Among theper well (panel A) or MRC5, 2000 cells per well (panel B) were incubated for 3 days
e determining percentage inhibition of the ﬂuorescent signal compared to controls
) 8.10  0.54 nM; melarsoprol (closed circles) 7.52  0.28 nM; suramin (open squares)
2.4  1.1 mM. Doxorubicin yielded an EC50 of 85.9  38.2 nM.
Table 1
Initial submicromolar hits from the LOPAC library returning EC50 vs. T. brucei
greater than 1mM.
Compound EC50 vs. T. brucei (mM)
Parthenolide 1.06 0.08
CB 1954a 1.08 0.09
Cyclosporin A 1.140.17
Bromoacetyl alprenolol menthane 1.260.14
Indirubin-30-oxime 1.280.09
Dipropyldopamine hydrobromide 1.290.06
SB 224289 hydrochlorideb 1.350.28
R()-Propylnorapomorphine hydrochloride 1.520.21
1,3-PBIT dihydrobromidec 1.580.08
Caffeic acid phenethyl ester 1.640.13
Kenpaullone 1.860.27
CGS-15943d 1.970.21
A-77636 hydrochloridee 2.210.15
Retinoic acid p-hydroxyanilide 2.230.27
6-Hydroxymelatonin 3.310.23
S-(4-Nitrobenzyl)-6-thioinosine 3.780.55
S-(p-Azidophenacyl)glutathione >10
Dephostatin >10
20 ,30-Dideoxycytidine >10
a 5-(1-Aziridinyl)-2,4-dinitrobenzamide.
b 10-Methyl-5-([20-methyl-40-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]
carbonyl)-2,3,6,7-tetrahydro-spiro(furo[2,3-f]indole-3,40-piperidine).
c Phenylene-1,3-bis(ethane-2-isothiourea) dihydrobromide.
d 9-Chloro-2-(2-furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine.
e ()-(1R,3S)-3-Adamantyl-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-
benzopyran hydrochloride hydrate.
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with activity against protein kinases, topoisomerases, tubulin, as well
as DNA and energy metabolism. The average Z0 scores throughout the
testing was 0.66 for T. brucei assays and 0.57 for MRC5 assays, values
characteristic of high quality cell-based screening assays.Table 2
Submicromolar hits against T. brucei ranked by selectivity vs. MRC5 cells.
Compound EC50 vs. T. brucei (nM
Pentamidine isethionate 3.70.10
Suramin hexasodium 683.5
(+)-trans-(1R,2R)-U-50488 hydrochloride 592.2
() trans-U-50488 methanesulfonate 1137.6
Dequalinium dichloride 438.8
Oligomycin A 1503.1
Mitoxantrone 2.40.20
8-(4-Chlorophenylthio)-cAMP sodium 40054
Chelerythrine chloride 595.7
Pimozide 34019
8-Cyclopentyl-1,3-dipropylxanthine 53053
4-Chloromercuribenzoic acid 69085
Dihydroergocristine methanesulfonate 89057
Dequalinium analogue, C-14 linker 70.04.6
Calmidazolium chloride 51066
Purvalanol A 82055
Beta-Lapachone 850130
Vinblastine sulfate salt 946.0
CGP-74514Aa 2108.3
Sanguinarine chloride 24017
Diphenyleneiodonium chloride 1207.6
Sphingosine 82078
Quinacrine dihydrochloride 38013
SKF 89145 hydrobromideb 61044
Calcimycin 18013
Idarubicin 201.5
Emetine dihydrochloride hydrate 7.90.53
Ellipticine 46045
Mevastatin 94050
Taxol 3.30.071
(S)-(+)-Camptothecin 53013
Alsterpaullone 40040
Vincristine sulfate 301.0
a N2-(cis-2-Aminocyclohexyl)-N6-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine H
b 4-(3,4-Dihydroxyphenyl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine HBr.3.5. Conﬁrmation of inhibition by (+)-U50,488 and other opioid
receptor ligands
A sample of (+)-U50,488 and eight other compounds known to
act on m- or k-opioid receptors were purchased for EC50
determination. The mean weighted to standard error was
58.9 nM for the authentic (+)-U50,488 sample compared to the
60 nM value found during the library screening. Of the other opioid
receptor ligands with structural similarity to (+)-U50,488, three
displayed EC50 values 5mM (Fig. 3) and one (U69593) was
inactive. Of the compounds showing structural similarity to
morphine, only buprenorphine showed weak activity. Thus, the
original (+)-U50,488 hit had the highest potency of this group of
compounds and was 70 times more potent than its trans
enantiomer, ()-U50,488.
3.6. k-Opioid receptor homology searching
Global alignments of the amino acid sequences of the k-
opioid receptor from sheep, zebraﬁsh, rough skinned newt,
mouse and guinea pig return similarity scores of 60–99%.
TBLASTN searching of the T. brucei GeneDB with these query
sequences revealed several predicted genes with only short
stretches of alignment. Global alignments of these predicted
genes with the known receptor sequences returned similarity
scores of only 9–19%.
3.7. Effect of (+)-U50,488 on T. brucei in vivo
Pharmacokinetic studies on (+)-U50,488 in uninfected mice
were performed. The compound is not tightly bound to mouse
plasma proteins (fraction unbound is 0.69) and is well tolerated) EC50 vs. MRC5 (nM) Selectivity
130006800 3400
>50000 >710
160004900 270
260008700 230
61001500 140
180002600 120
11037 46
1800012000 44
2500480 42
140003300 41
170007900 31
190003000 27
20000770 23
1000 290 14
6600750 13
100003200 12
86002900 10
780910 8.3
1500620 7.1
1400350 5.8
700870 5.7
46002500 5.7
1900440 5.0
2900200 4.7
750140 4.2
7829 3.9
303.1 3.8
1700620 3.7
2000360 2.2
6.69.8 2
80099 1.5
510170 1.3
0.601.0 0.02
Cl.
[(Fig._3)TD$FIG]
Fig. 3. Structure–activity relationships of opioid receptor ligands against T. brucei. These compounds were screened for potency against T. brucei. EC50 values are recorded as
the weighted mean of 3 determinations. Norbinaltorphimine was tested at a maximum concentration of 50 mM due to solubility issues.
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blood ratio was 8.2, an excellent property for a stage 2 candidate
HAT drug. The peak free blood concentration of (+)-U50,488 was
800 ng ml1 1 h after dosing with a half-life of 2.6  0.04 h (Fig. 4).
Based on these ﬁndings, 3micewere infectedwith T. brucei and dosed
orally at 150 mg kg1 every 4 h for 32 h to ensure that the free blood
level remained above the EC99. However, this regimen was not
curative, with only one mouse showing a transient reduction in
parasitaemia followed by relapse, in sharp contrast to our recent
studies on inhibitors of N-myristoyltransferase [25] and nitroaro-
matic drugs [18].3.8. Effect of (+)-U50,488 and HAT drugs on T. brucei culture growth
Toexamine thecauseof thepoor trypanocidal activity in vivo, (+)-
U50,488was comparedwith theknownHATdrugspentamidineand
eﬂornithine for their ability tokill or slowthegrowthofT. brucei cells
in culture (Fig. 5). Exposure to pentamidine (10  EC50) caused the
cell density to drop below the limit of detection (1 103 cells ml1)
by 40 h with no viable cells visible by microscopy, indicating a
cytocidal effect. Eﬂornithine arrested cell growth after 30 h and cell
density did not change thereafter, indicating a cytostatic effect. In
contrast, exposure to (+)-U50,488 at 10 EC50 only had a minor
[(Fig._4)TD$FIG]
Fig. 4. Pharmacokinetic properties of (+)-U50,488 in mice. Data show the mean and
standard error for the free blood concentration in 3mice following a single oral dose
at 150 mg kg1. The calculated half-life is 2.60  0.04 h. The dashed lines indicate the
EC50 obtained in vitro against T. brucei and the predicted EC90 and EC99 values for
growth inhibition.
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Further inspectionof the EC50 curves suggested that this unexpected
result might be attributed to a low Hill slope for this compound.
Based on the EC50 values and Hill slopes for pentamidine and
eﬂornithine (8 nM, s = 3.1 and 22.4mM, s = 4.0, respectively) EC99
values of 37 nM and 77mM can be calculated, values which are less
than10 times EC50. In contrast, (+)-U50,488 (EC50 60 nM, s = 1.8) has
a predicted EC99 value of 740 nM,which is greater than 10 times the
EC50. Thus, the observed partial inhibition of growth is consistent
with exposure to this concentration of drug. In a series of additional
experiments the effect on growth of 50, 100 and 500 times the EC50
for (+)-U50,488was examined. These concentrations showed a dose
dependent reduction in growth rate, but only at the highest drug
concentration (30mM, 500 times EC50) was it possible to achieve a
cytocidal effect (Fig. 5, closed squares).
4. Discussion
Our experiments establish that resazurin can be used as a
cheaper substitute for the alamarBlue1 formulation for growth
[(Fig._5)TD$FIG]Fig. 5. Effect of inhibitors on T. brucei growth in vitro. T. bruceiwere grown in 10-ml
cultures in the presence of the inhibitors at 10 times (open symbols) and 500 times
(closed symbols) their EC50 values. Cells were counted using a haemocytometer
over a 3-day period. Values are the mean and standard deviation of three ﬂasks and
are representative of three independent experiments. No drug, circles; (+)-U50,488,
squares; eﬂornithine, triangles; pentamidine, inverted triangle. Cell counts below
the limits of detection are indicated by a skull and crossbones symbol.inhibition assays for bloodstream-form T. brucei or human
ﬁbroblasts. However, this assay method does not necessarily
indicate cell death. Inhibitors could be cytocidal, cytostatic, or
interfering with the reduction of resazurin without effect on cell
growth. Lead compounds must therefore be assessed for cytotox-
icity by alternative means such as direct cell counting of viable
parasites (Fig. 5) or a ‘live–dead assay’ [26]. The HMI9-T medium
used in this assay has been shown to mask inhibition of certain
metabolic pathways such as folate metabolism and thymidylate
biosynthesis [27] and consequently these inhibitors are unlikely to
be identiﬁed with these culture conditions. Given this proviso, our
results indicate that this semi-automated medium-throughput
screeningmethod against T. brucei is reproducible and robust.With
further automation and miniaturisation it could be used to screen
much larger compound collections and other special focussed sets
available in our Drug Discovery Unit [28].
The drugs currently used to treat HAT show a wide range of
potencies in this assay, ranging from 8 nM for pentamidine and
melarsoprol to 1.8 mM for nifurtimox and 22mM for eﬂornithine.
Despite many current drug-discovery paradigms being driven by
potency – at least at the early stages of lead identiﬁcation – the
example of eﬂornithine demonstrates that lower potency com-
pounds may still emerge as effective treatments. Any lead offering
improvement on either the mode of administration or cost of
eﬂornithine regimenwould be an advance in the treatment of HAT.
The EC50 values determined by Likeufack et al. against T. b.
gambiense vary by amaximumof 4.5-fold between stocks [15], and
the values we report against T. b. brucei fall within these ranges.
The same is true for the values reported by Raz et al. [13] for T. b.
rhodesiense. However, although T. b. brucei, which is non-
pathogenic to humans, is a suitable model for HAT, it is important
to test advanced lead compounds against these clinically relevant
subspecies.
The 33 inhibitors of T. bruceiwith nanomolar potency identiﬁed
from the LOPAC collection included pentamidine and suramin
which acted as internal controls. The minor differences in EC50
values between the library screening and our testing of standard
compounds could be due to higher purity in the original samples
purchased and evaporation in the smaller volumes of the library
samples. Original hits that were rejected at the 1mM cut-off
include several compounds that have known pharmacological
activity in animal models. Testing these against rodent models of
HAT at the already-established maximum tolerated doses could
identify additional promising leads.
Six out of the 33 hits with EC50 values less than 1mM showed
more than 100-fold selectivity for T. brucei. Pentamidine and
suramin were the most selective compounds identiﬁed, illustrat-
ing the target selectivity (>1000-fold) that should be aimed for at
the ﬁnal stages of lead development. The most selective
compounds previously unknown to inhibit T. brucei were from
isomers of U50,488, a known agonist of the k-opioid receptor [29].
This compound shows good brain penetration and therefore
potentially able to access a late-stage HAT infection, a key feature
speciﬁed by the current target product proﬁle from WHO.
From the limited number of commercially available opioid
receptor ligands, (+)-U50,488 was the most potent (Fig. 4). Other
compounds showed either weak or no activity. The complete lack
of activity of norbinaltorphimine against T. rucei suggests that
possible CNS side effects of a treatment based on (+)-U50,488 could
be reduced by co-administration of a k-opioid antagonist. Whilst
the (-)-U50,488 isomer is a stronger agonist of the k-opioid
receptor than the (+)-U50,488 isomer, the latter is almost 70 times
more effective against T. brucei. k-Opioid receptors typically share
high similarity at the amino acid level across species as indicated
by our homology searching. However, consistent with the poor
activity of other opioid receptor ligands, we found no convincing
D.C. Jones et al. / Biochemical Pharmacology 80 (2010) 1478–14861486homologue of the receptor in the T. brucei genome. An opioid
receptor agonist (endomorphin-1; YPWF-NH2) has been shown to
inhibit a drug-metabolite transporter from the malaria parasite
Plasmodium falciparum [30]. Mutations in this transporter confer
resistance to chloroquine, but unfortunately the physiological
substrates are not known [31]. Moreover, no convincing homo-
logues could be identiﬁed in the T. brucei genome database. Thus,
the target for U50,488 remains to be identiﬁed in T. brucei.
The in vivo and in vitro experiments indicate that further
optimization of (+)-U50,488 is required to achieve efﬁcacy.
Although the compound has good pharmacological properties,
including high CNS penetration, it was not curative using a
therapeutic schedule which was predicted to maintain free blood
exposure above the predicted EC99. The reason for this is not
entirely clear. The in vitro studies demonstrated that the
compound is cytostatic at 100 times the EC50, like eﬂornithine,
rather than cytocidal, like pentamidine. Thus, continuous expo-
sure above the minimum inhibitory concentration may be
required to allow sufﬁcient time for the immune system to
eliminate non-dividing parasites, as is the case with eﬂornithine.
Alternatively, differences in the physiological environment in vivo
and in vitro may be responsible for the lack of efﬁcacy. Further
studies on the mode of action of (+)-U50,488 would be
informative. Although a cytocidal effect was observed at high
concentrations (30 mM, 500 times EC50), this could be due to
additional off-target effects and, in any case, is above the
maximum free blood concentration achievable under the dosing
schedule used here.
Futureworkwill involve furthermedicinal chemistry to explore
structure–activity relationships, improve potency and the Hill
slope. It remains to be seen whether the cytostatic effect of
U50,488 is a function of the target(s) or the inhibitor itself.
Identifying the intracellular target of U50,488 could provide a new
avenue for drug discovery efforts against T. brucei.
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